Human Epidermal Growth Factor Receptor 2–Targeting [<sup>68</sup>Ga]Ga-ABY-025 PET/CT Predicts Early Metabolic Response in Metastatic Breast CancerAli Alhuseinalkhudhur, Jens Nørkær Sørensen, Vladimir Tolmachev et al.|Journal of Nuclear Medicine|2023Cited by 49
Diagnostic HER2-binding radiopharmaceutical, [<sup>68</sup>Ga]Ga-ABY-025, for routine clinical use in breast cancer patients.Irina Velikyan, Jens Nørkær Sørensen, Philip Schweighöfer et al.|PubMed|2019Cited by 38
Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancerAli Alhuseinalkhudhur, Jens Nørkær Sørensen, Mark Lubberink et al.|EJNMMI Research|2020Cited by 25
Abstract P3-02-06: A phase II study of 68Ga-ABY-025 PET for non-invasive quantification of HER2 expression in breast cancerAli Alhuseinalkhudhur, Jens Christian Hedemann Sørensen, Henrik Lindman et al.|Cancer Research|2022Cited by 1
[<sup>68</sup>Ga]Ga-ABY-025 PET in HER2-positive breast cancer: Benefits and pitfalls in staging of axillary disease.Ali Alhuseinalkhudhur, Jens Benn Sørensen, Henrik Lindman et al.|Journal of Clinical Oncology|2024Cited by 1